TY - JOUR
T1 - Hyperprogression and Immunotherapy
T2 - Fact, Fiction, or Alternative Fact?
AU - Adashek, Jacob J.
AU - Subbiah, Ishwaria M.
AU - Matos, Ignacio
AU - Garralda, Elena
AU - Menta, Arjun K.
AU - Ganeshan, Dhakshina Moorthy
AU - Subbiah, Vivek
N1 - Publisher Copyright:
© 2020 The Author(s)
PY - 2020/3
Y1 - 2020/3
N2 - Immunotherapy (IO) has altered the therapeutic landscape for multiple cancers. There are emerging data from retrospective studies on a subset of patients who do not benefit from IO, instead experiencing rapid progression with dramatic acceleration of disease trajectory, termed ‘hyperprogressive disease’ (HPD). The incidence of HPD ranges from 4% to 29% from the studies reported. Biological basis and mechanisms of HPD are currently being elucidated, with one theory involving the Fc region of antibodies. Another group has shown EGFR and MDM2/MDM4 amplifications in patients with HPD. This phenomenon has polarized oncologists who debate that this could still reflect the natural history of the disease. Thus, prospective studies are urgently needed to confirm the underlying biology, predict patients who are susceptible to HPD, and determine the modality of therapy post progression.
AB - Immunotherapy (IO) has altered the therapeutic landscape for multiple cancers. There are emerging data from retrospective studies on a subset of patients who do not benefit from IO, instead experiencing rapid progression with dramatic acceleration of disease trajectory, termed ‘hyperprogressive disease’ (HPD). The incidence of HPD ranges from 4% to 29% from the studies reported. Biological basis and mechanisms of HPD are currently being elucidated, with one theory involving the Fc region of antibodies. Another group has shown EGFR and MDM2/MDM4 amplifications in patients with HPD. This phenomenon has polarized oncologists who debate that this could still reflect the natural history of the disease. Thus, prospective studies are urgently needed to confirm the underlying biology, predict patients who are susceptible to HPD, and determine the modality of therapy post progression.
KW - cancer clinical trials
KW - hyperprogressive disease
KW - immune checkpoint inhibitors
KW - immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85078833844&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078833844&partnerID=8YFLogxK
U2 - 10.1016/j.trecan.2020.01.005
DO - 10.1016/j.trecan.2020.01.005
M3 - Review article
C2 - 32101722
AN - SCOPUS:85078833844
SN - 2405-8033
VL - 6
SP - 181
EP - 191
JO - Trends in Cancer
JF - Trends in Cancer
IS - 3
ER -